DeepMed Research

Yuhan Corporation

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors

Phase 1

Not yet recruiting

Conditions: EGFR Overexpression
Locally Advanced Solid Tumor
Metastatic Solid Tumor

Interventions: Drug: YH32364

First Posted Date: 2025-05-16

Last Posted Date: 2025-05-16

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 80

Registration Number: NCT06975410

Locations: 🇰🇷
Korea University Anam Hospital, Seoul, Korea, Republic of
🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
🇰🇷
Severance Hospital, Seoul, Korea, Republic of

and more 1 locations

Bioequivalence Study betweenYHP2407 and YHR2502 in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: YHP2407
Drug: YHR2502

First Posted Date: 2025-04-13

Last Posted Date: 2025-05-13

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 43

Registration Number: NCT06926387

Locations: 🇰🇷
Gimpo Woori Hospital, Gimpo-si, Gyeonggi-do, Korea, Republic of

Bioequivalence Study betweenYHP2406 and YHR2501 in Healthy Subjects

Phase 1

Not yet recruiting

Conditions: Healthy Subject

Interventions: Drug: YHP2406
Drug: YHR2501

First Posted Date: 2025-04-10

Last Posted Date: 2025-04-10

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 62

Registration Number: NCT06920719

Locations: 🇰🇷
H Plus Yangji Hospital, Seoul, Korea, Republic of

Bioequivalence (BE) Study Between YHP2205 and YHR2401 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: YHP2205
Drug: YHR2401

First Posted Date: 2025-01-15

Last Posted Date: 2025-02-03

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 60

Registration Number: NCT06775522

Locations: 🇰🇷
Bumin Hospital, Seoul, Gangseo-gu, Korea, Republic of

Clinical Trial to Evaluate the Safety and Efficacy of NTCB02-1 in Patients Who Require Parenteral Nutrition

Phase 3

Recruiting

Conditions: Parenteral Nutrition

Interventions: Drug: NTCB02-1
Drug: NTCB-C

First Posted Date: 2024-10-03

Last Posted Date: 2025-03-25

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 60

Registration Number: NCT06625957

Locations: 🇰🇷
National Cancer Center, Gyeonggi-do, Goyang-si, Korea, Republic of
🇰🇷
Chonnam National University Hwasun Hospital, Jeollanam-do, Hwasun-gun, Korea, Republic of
🇰🇷
Jeonbuk National University Hospital, Jeollabuk-do, Jeonju-si, Korea, Republic of

and more 2 locations

Clinical Trial to Evaluate the Safety and Efficacy of NTCB01-1 in Patients Who Require Parenteral Nutrition

Phase 3

Completed

Conditions: Parenteral Nutrition

Interventions: Drug: NTCB01-1
Drug: NTCB-P

First Posted Date: 2024-10-03

Last Posted Date: 2025-05-15

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 60

Registration Number: NCT06625931

Locations: 🇰🇷
Keimyung University Dongsan Hospital, Daegu, Dalseo-gu, Korea, Republic of
🇰🇷
Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Dongjak-gu, Korea, Republic of
🇰🇷
Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of

and more 4 locations

Clinical Trial to Evaluate the PK Interactions of YHR2402 Monotherapy and YHR2402 and YHR2403 Co-Administration in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: YHR2402
Drug: YHR2402+YHR2403

First Posted Date: 2024-10-02

Last Posted Date: 2024-11-22

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 26

Registration Number: NCT06623526

Locations: 🇰🇷
Jeonbuk National University Hospital, Jeonju, Korea, Republic of

A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946

Phase 1

Recruiting

Conditions: NSCLC (Non-small Cell Lung Cancer)
Solid Tumor

Interventions: Drug: YH42946

First Posted Date: 2024-09-27

Last Posted Date: 2025-03-27

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 161

Registration Number: NCT06616766

Locations: 🇰🇷
Chungbuk National University Hospital, Cheongju-si, Chungcheongbuk-do, Korea, Republic of
🇰🇷
Asan Medical Center, University of Ulsan, Seoul, Korea, Republic of
🇺🇸
Next Oncology Virginia, Fairfax, Virginia, United States

and more 5 locations

Bioequivalence Study Between YHP2305 and YHR2404 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: YHP2305
Drug: YHR2404

First Posted Date: 2024-09-25

Last Posted Date: 2024-11-15

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 34

Registration Number: NCT06613139

Locations: 🇰🇷
Bumin Hospital, Seoul, Korea, Republic of

A First-in-Human, Single- and Multiple-Ascending Dose Study of YH35995 in Healthy Adult Male Participants

Phase 1

Recruiting

Conditions: Healthy Participants

Interventions: Drug: YH35995
Drug: Placebo

First Posted Date: 2024-07-24

Last Posted Date: 2024-11-21

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 96

Registration Number: NCT06517914

Locations: 🇰🇷
CHA Bundang Medical Center, Seongnam, Bundang-gu, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy